Welcome to Paid Research Studies




  • Condition:   Philadelphia Chromosome Negative Adult B-cell Acute Lymphoblastic Leukemia
    Intervention:  
    Sponsor:   Assistance Publique - Hôpitaux de Paris
    Recruiting

  • Condition:   Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
    Intervention:   Drug: blinatumomab
    Sponsor:   PETHEMA Foundation
    Recruiting

  • Conditions:   Chromosome Aberrations;   Growth Hormone Deficiency;   Hypomyelination
    Interventions:   Procedure: Determination of growth hormone status;   Procedure: Measurement of growth, thyroid and sex hormone levels;   Procedure: Behavior and neuropsychometric evaluations;   Procedure: Audiological and ear, nose and throat examination;   Procedure: Magnetic resonance imaging of the brain;   Procedure: Dysmorphology evaluation;   Procedure: Neurology examination;   Procedure: Dental evaluation;   Procedure: Speech pathology evaluation;   Procedure: Psychiatric evaluation;   Procedure: Orthopedic evaluation;   Procedure: Ophthalmologic evaluation;   Procedure: Gastrointestinal evaluation
    Sponsor:   The University of Texas Health Science Center at San Antonio
    Recruiting

  • Conditions:   Chromosome Abnormality;   Abnormality
    Intervention:   Diagnostic Test: Noninvasive chromosome screening
    Sponsor:   Instituto Bernabeu
    Recruiting

  • Conditions:   Aneuploidy;   Chromosome Abnormality
    Intervention:   Diagnostic Test: PGT-A
    Sponsor:   Igenomix
    Recruiting

  • Conditions:   Urothelial Carcinoma;   Diagnoses Disease;   Chromosomal Abnormality;   Urine Marking
    Intervention:   Diagnostic Test: Low-coverage whole-genome sequencing of urine exfoliated cells
    Sponsor:   Changhai Hospital
    Recruiting

  • Conditions:   Intrauterine Growth Restriction;   Fetal Anomaly;   Chromosomal Anomalies;   Pregnancy
    Intervention:  
    Sponsor:   Guangzhou Women and Children's Medical Center
    Recruiting

  • Conditions:   Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
    Interventions:   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Lymphoblastic Leukemia, Acute, Adult;   Acute Lymphoid Leukemia;   Leukemia, Acute Lymphoblastic;   Leukemia, Lymphoblastic;   Ph1 Chromosome;   Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
    Interventions:   Drug: Ponatinib;   Drug: Imatinib;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Prednisone
    Sponsor:   Millennium Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia;   Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
    Interventions:   Drug: ABL001;   Drug: ABL001 + Nilotinib;   Drug: ABL001+imatinib;   Drug: ABL001+dasatinib
    Sponsor:   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Klinefelter Syndrome;   Trisomy X;   XYY Syndrome;   XXXY and XXXXY Syndrome;   Xxyy Syndrome;   Xyyy Syndrome;   Xxxx Syndrome;   Xxxxx Syndrome;   Xxxyy Syndrome;   Xxyyy Syndrome;   Xyyyy Syndrome;   Male With Sex Chromosome Mosaicism
    Intervention:   Other: Assessments of Development and Growth
    Sponsor:   University of Colorado, Denver
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   T Acute Lymphoblastic Leukemia;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Dexrazoxane Hydrochloride;   Drug: Doxorubicin;   Drug: Etoposide;   Biological: Filgrastim;   Drug: Ifosfamide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Methylprednisolone;   Drug: Pegaspargase;   Drug: Prednisolone;   Other: Questionnaire Administration;   Drug: Therapeutic Hydrocortisone;   Drug: Thioguanine;   Drug: Vincristine Sulfate
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI);   University of Milano Bicocca
    Recruiting

  • Conditions:   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive;   Recurrent Acute Lymphoblastic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Acute Lymphoblastic Leukemia;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   t(9;22)
    Interventions:   Drug: Dexamethasone;   Drug: Ponatinib Hydrochloride;   Biological: Rituximab;   Drug: Venetoclax
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia;   BCR-ABL1 Fusion Protein Expression;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive;   Recurrent Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia;   t(9;22)
    Interventions:   Biological: Blinatumomab;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Ponatinib
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   Amgen;   Takeda
    Recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia With BCR-ABL1;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive;   Recurrent Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Biological: Filgrastim;   Drug: Methotrexate;   Biological: Pegfilgrastim;   Drug: Ponatinib;   Biological: Rituximab;   Drug: Vincristine
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Acute Lymphoblastic Leukemia
    Intervention:   Drug: Dasatinib and blinatumomab
    Sponsor:   Gruppo Italiano Malattie EMatologiche dell'Adulto
    Not yet recruiting

  • Conditions:   Male Factor Infertility;   Female Factor Infertility
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting

  • Conditions:   Adult B Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive
    Interventions:   Biological: Blinatumomab;   Drug: Ibrutinib
    Sponsors:   Brian Jonas;   National Cancer Institute (NCI);   Pharmacyclics LLC.
    Recruiting

  • Condition:   Mitochondrial Diseases
    Intervention:  
    Sponsor:   Centre Hospitalier Universitaire de Nice
    Recruiting

  • Condition:   Relapsed/Refractory Acute Lymphoblastic Leukemia
    Intervention:   Other: Other
    Sponsor:   Amgen
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia;   Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
    Intervention:   Drug: Ponatinib
    Sponsor:   Korea Otsuka Pharmaceutical Co., Ltd.
    Recruiting

  • Conditions:   Aneuploidy;   Chromosome Abnormality;   Infertility
    Interventions:   Diagnostic Test: PGT-A;   Diagnostic Test: niPGT-A
    Sponsor:   Igenomix
    Recruiting

  • Conditions:   Aneuploidy;   Chromosome Abnormality;   Infertility
    Interventions:   Diagnostic Test: niPGT-A;   Other: Morphology criteria
    Sponsor:   Igenomix
    Not yet recruiting

  • Conditions:   B-cell Acute Lymphoblastic Leukemia;   Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis;   Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL
    Interventions:   Drug: ABL001;   Drug: Dasatinib;   Drug: Prednisone
    Sponsors:   Marlise R. Luskin;   Novartis
    Recruiting

  • Conditions:   Loss of Chromosome 17p;   Recurrent Plasma Cell Myeloma
    Interventions:   Drug: Dexamethasone;   Drug: Idasanutlin;   Drug: Ixazomib Citrate;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study
    Sponsors:   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Loss of Chromosome 17p
    Interventions:   Drug: Ibrutinib;   Drug: Venetoclax
    Sponsors:   Kerry Rogers;   National Cancer Institute (NCI);   Janssen Research & Development, LLC
    Not yet recruiting

  • Conditions:   Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Acute Lymphoblastic Leukemia;   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Philadelphia Chromosome Positive;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Other: Laboratory Biomarker Analysis;   Drug: Methotrexate;   Drug: Ponatinib;   Drug: Ponatinib Hydrochloride;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Autosomal Recessive Disorder;   Aneuploidy
    Intervention:   Other: Computer-Aided Genetic Education Module
    Sponsor:   Wayne State University
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   CD22 Positive;   Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
    Interventions:   Drug: Bosutinib;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Biological: Inotuzumab Ozogamicin;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Lymphoblastic Lymphoma;   Philadelphia Chromosome Positive
    Interventions:   Drug: Cyclophosphamide;   Drug: Dasatinib;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Imatinib Mesylate;   Other: Laboratory Biomarker Analysis;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   University of Washington;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1;   Recurrent Adult Acute Lymphoblastic Leukemia;   Refractory Adult Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Drug: Dasatinib;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Prednisone;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Pulmonary Nodule, Solitary
    Intervention:   Diagnostic Test: FISH
    Sponsors:   Tianjin Medical University Cancer Institute and Hospital;   Zhuhai livzon cynvenio diagnostics LTD
    Recruiting

  • Conditions:   CD19 Positive;   Philadelphia Chromosome Positive;   Recurrent Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis;   Biological: Pembrolizumab
    Sponsors:   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia;   CML;   Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia;   Ph+ ALL
    Intervention:  
    Sponsor:   Incyte Biosciences Benelux
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   CD22 Positive;   Recurrent B Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia
    Interventions:   Biological: Blinatumomab;   Biological: Inotuzumab Ozogamicin
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative;   BCR/ABL1 Fusion Protein Negative;   Untreated Adult Acute Lymphoblastic Leukemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Dexamethasone;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Pegaspargase;   Drug: Prednisone;   Biological: Rituximab;   Drug: Vincristine Sulfate
    Sponsors:   National Cancer Institute (NCI);   Canadian Cancer Trials Group
    Recruiting

  • Conditions:   Cerebral Palsy;   Neurologic Disorder;   Chromosome Abnormality;   Spina Bifida
    Interventions:   Device: Lite Run Gait Trainer;   Other: Usual Treatments
    Sponsors:   Gillette Children's Specialty Healthcare;   Lite Run Inc.
    Recruiting

  • Conditions:   Chronic Phase Chronic Myelogenous Leukemia;   Accelerated Phase Chronic Myelogenous Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
    Intervention:  
    Sponsor:   Incyte Biosciences UK
    Recruiting

  • Conditions:   Adult Acute Lymphoblastic Leukemia in Complete Remission;   B Acute Lymphoblastic Leukemia;   Minimal Residual Disease;   Philadelphia Chromosome Positive
    Interventions:   Biological: Blinatumomab;   Other: Laboratory Biomarker Analysis
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   CD22 Positive;   Philadelphia Chromosome Positive;   Recurrent B Acute Lymphoblastic Leukemia;   Refractory B Acute Lymphoblastic Leukemia
    Intervention:   Biological: ADCT-602
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI);   ADC Therapeutics S.A.
    Recruiting

  • Conditions:   CML, Chronic Phase;   CML (Chronic Myelogenous Leukemia;   CML - Philadelphia Chromosome;   Chronic Myeloid Leukemia;   Chronic Myeloid Leukemia, Chronic Phase
    Interventions:   Drug: Bosutinib;   Drug: Dasatinib;   Drug: Imatinib;   Drug: Nilotinib
    Sponsor:   UNC Lineberger Comprehensive Cancer Center
    Recruiting

  • Conditions:   Trisomy 21;   Trisomy 18;   Trisomy 13;   Sex Chromosome Abnormalities;   Microdeletion Syndromes
    Intervention:  
    Sponsor:   Natera, Inc.
    Recruiting

  • Condition:   ALL
    Interventions:   Drug: Prednisone;   Drug: Vincristine;   Drug: Daunorubicin;   Drug: Ponatinib;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: VP-16;   Drug: ARA-C:;   Drug: TIT;   Procedure: Autologous transplantation;   Procedure: Allo transplantation
    Sponsor:   PETHEMA Foundation
    Recruiting

  • Condition:   Kidney Cancer
    Interventions:   Other: Radiologic Centralized Review;   Other: Tissue sample (tumor, sung, urine)
    Sponsor:   Assistance Publique Hopitaux De Marseille
    Not yet recruiting

  • Condition:   Chronic Myeloid Leukemia, Chronic Phase
    Interventions:   Drug: Radotinib;   Drug: Imatinib
    Sponsor:   Il-Yang Pharm. Co., Ltd.
    Recruiting

  • Condition:   Infertility
    Intervention:  
    Sponsor:   Reproductive Medicine Associates of New Jersey
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia (for Part B and C);   Healthy (For Part A)
    Interventions:   Drug: K0706;   Drug: Placebo
    Sponsor:   Sun Pharma Advanced Research Company Limited
    Recruiting

  • Condition:   Phelan McDermid Syndrome
    Intervention:   Drug: Recombinant human Growth hormone
    Sponsor:   Swathi Sethuram
    Recruiting

  • Conditions:   Chronic Myeloid Leukemia;   Leukemia, Myelogenous, Chronic, BCR-ABL Positive
    Intervention:   Drug: PF-114
    Sponsors:   Fusion Pharma LLC;   OCT Rus, LLC;   Data Matrix Solutions;   Skolkovo Innovation Center
    Recruiting

  • Condition:   Phelan-McDermid Syndrome
    Interventions:   Drug: Oxytocin;   Drug: Saline
    Sponsor:   Alexander Kolevzon
    Recruiting

  • Conditions:   Chronic Myelogenous Leukemia, Ph1-Positive;   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: BP1001 (varying dose);   Drug: BP1001 (fixed dose);   Drug: Dasatinib
    Sponsor:   Bio-Path Holdings, Inc.
    Recruiting

  • Conditions:   22q13 Deletion Syndrome;   Phelan-McDermid Syndrome
    Interventions:   Drug: Insulin-Like Growth Factor-1 (IGF-1);   Drug: Normal saline
    Sponsors:   Icahn School of Medicine at Mount Sinai;   National Institute of Mental Health (NIMH)
    Recruiting

  • Conditions:   Acute Leukemias of Ambiguous Lineage;   B-cell Adult Acute Lymphoblastic Leukemia;   Philadelphia Chromosome Positive Adult Precursor Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma
    Interventions:   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Drug: prednisone;   Biological: inotuzumab ozogamicin;   Other: laboratory biomarker analysis
    Sponsors:   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Fragile X Syndrome;   Fragile X Mental Retardation Syndrome;   Mental Retardation, X-Linked;   Genetic Diseases, X-Linked;   Trinucleotide Repeat Expansion;   Fra(X) Syndrome;   Intellectual Disability;   FXS;   Neurobehavioral Manifestations;   Sex Chromosome Disorders
    Interventions:   Drug: Placebo Medication;   Drug: Metformin
    Sponsors:   University of Alberta;   St. Justine's Hospital
    Recruiting

  • Conditions:   Fragile X Syndrome;   Fragile X Mental Retardation Syndrome;   Mental Retardation, X Linked;   Genetic Diseases, X-Linked;   Trinucleotide Repeat Expansion;   Fra(X) Syndrome;   Intellectual Disability;   FXS;   Neurobehavioral Manifestations;   Sex Chromosome Disorders
    Interventions:   Drug: Placebo Medication;   Drug: Metformin
    Sponsor:   University of California, Davis
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Allogeneic Hematopoietic Stem Cell Transplantation Recipient;   B Acute Lymphoblastic Leukemia;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   Recurrent B Acute Lymphoblastic Leukemia
    Intervention:   Biological: Inotuzumab Ozogamicin
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Rare Disorders;   Undiagnosed Disorders;   Disorders of Unknown Prevalence;   Cornelia De Lange Syndrome;   Prenatal Benign Hypophosphatasia;   Perinatal Lethal Hypophosphatasia;   Odontohypophosphatasia;   Adult Hypophosphatasia;   Childhood-onset Hypophosphatasia;   Infantile Hypophosphatasia;   Hypophosphatasia;   Kabuki Syndrome;   Bohring-Opitz Syndrome;   Narcolepsy Without Cataplexy;   Narcolepsy-cataplexy;   Hypersomnolence Disorder;   Idiopathic Hypersomnia Without Long Sleep Time;   Idiopathic Hypersomnia With Long Sleep Time;   Idiopathic Hypersomnia;   Kleine-Levin Syndrome;   Kawasaki Disease;   Leiomyosarcoma;   Leiomyosarcoma of the Corpus Uteri;   Leiomyosarcoma of the Cervix Uteri;   Leiomyosarcoma of Small Intestine;   Acquired Myasthenia Gravis;   Addison Disease;   Hyperacusis (Hyperacousis);   Juvenile Myasthenia Gravis;   Transient Neonatal Myasthenia Gravis;   Williams Syndrome;   Lyme Disease;   Myasthenia Gravis;   Marinesco Sjogren Syndrome(Marinesco-Sjogren Syndrome);   Isolated Klippel-Feil Syndrome;   Frasier Syndrome;   Denys-Drash Syndrome;   Beckwith-Wiedemann Syndrome;   Emanuel Syndrome;   Isolated Aniridia;   Beckwith-Wiedemann Syndrome Due to Paternal Uniparental Disomy of Chromosome 11;   Beckwith-Wiedemann Syndrome Due to Imprinting Defect of 11p15;   Beckwith-Wiedemann Syndrome Due to 11p15 Translocation/Inversion;   Beckwith-Wiedemann Syndrome Due to 11p15 Microduplication;   Beckwith-Wiedemann Syndrome Due to 11p15 Microdeletion;   Axenfeld-Rieger Syndrome;   Aniridia-intellectual Disability Syndrome;   Aniridia - Renal Agenesis - Psychomotor Retardation;   Aniridia - Ptosis - Intellectual Disability - Familial Obesity;   Aniridia - Cerebellar Ataxia - Intellectual Disability;   Aniridia - Absent Patella;   Aniridia;   Peters Anomaly - Cataract;   Peters Anomaly;   Potocki-Shaffer Syndrome;   Silver-Russell Syndrome Due to Maternal Uniparental Disomy of Chromosome 11;   Silver-Russell Syndrome Due to Imprinting Defect of 11p15;   Silver-Russell Syndrome Due to 11p15 Microduplication;   Syndromic Aniridia;   WAGR Syndrome;   Wolf-Hirschhorn Syndrome;   4p16.3 Microduplication Syndrome;   4p Deletion Syndrome, Non-Wolf-Hirschhorn Syndrome;   Autosomal Recessive Stickler Syndrome;   Stickler Syndrome Type 2;   Stickler Syndrome Type 1;   Stickler Syndrome;   Mucolipidosis Type 4;   X-linked Spinocerebellar Ataxia Type 4;   X-linked Spinocerebellar Ataxia Type 3;   X-linked Intellectual Disability - Ataxia - Apraxia;   X-linked Progressive Cerebellar Ataxia;   X-linked Non Progressive Cerebellar Ataxia;   X-linked Cerebellar Ataxia;   Vitamin B12 Deficiency Ataxia;   Toxic Exposure Ataxia;   Unclassified Autosomal Dominant Spinocerebellar Ataxia;   Thyroid Antibody Ataxia;   Sporadic Adult-onset Ataxia of Unknown Etiology;   Spinocerebellar Ataxia With Oculomotor Anomaly;   Spinocerebellar Ataxia With Epilepsy;   Spinocerebellar Ataxia With Axonal Neuropathy Type 2;   Spinocerebellar Ataxia Type 8;   Spinocerebellar Ataxia Type 7;   Spinocerebellar Ataxia Type 6;   Spinocerebellar Ataxia Type 5;   Spinocerebellar Ataxia Type 4;   Spinocerebellar Ataxia Type 37;   Spinocerebellar Ataxia Type 36;   Spinocerebellar Ataxia Type 35;   Spinocerebellar Ataxia Type 34;   Spinocerebellar Ataxia Type 32;   Spinocerebellar Ataxia Type 31;   Spinocerebellar Ataxia Type 30;   Spinocerebellar Ataxia Type 3;   Spinocerebellar Ataxia Type 29;   Spinocerebellar Ataxia Type 28;   Spinocerebellar Ataxia Type 27;   Spinocerebellar Ataxia Type 26;   Spinocerebellar Ataxia Type 25;   Spinocerebellar Ataxia Type 23;   Spinocerebellar Ataxia Type 22;   Spinocerebellar Ataxia Type 21;   Spinocerebellar Ataxia Type 20;   Spinocerebellar Ataxia Type 2;   Spinocerebellar Ataxia Type 19/22;   Spinocerebellar Ataxia Type 18;   Spinocerebellar Ataxia Type 17;   Spinocerebellar Ataxia Type 16;   Spinocerebellar Ataxia Type 15/16;   Spinocerebellar Ataxia Type 14;   Spinocerebellar Ataxia Type 13;   Spinocerebellar Ataxia Type 12;   Spinocerebellar Ataxia Type 11;   Spinocerebellar Ataxia Type 10;   Spinocerebellar Ataxia Type 1 With Axonal Neuropathy;   Spinocerebellar Ataxia Type 1;   Spinocerebellar Ataxia - Unknown;   Spinocerebellar Ataxia - Dysmorphism;   Non Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Spectrin-associated Autosomal Recessive Cerebellar Ataxia;   Spasticity-ataxia-gait Anomalies Syndrome;   Spastic Ataxia With Congenital Miosis;   Spastic Ataxia - Corneal Dystrophy;   Spastic Ataxia;   Rare Hereditary Ataxia;   Rare Ataxia;   Recessive Mitochondrial Ataxia Syndrome;   Progressive Epilepsy and/or Ataxia With Myoclonus as a Major Feature;   Posterior Column Ataxia - Retinitis Pigmentosa;   Post-Stroke Ataxia;   Post-Head Injury Ataxia;   Post Vaccination Ataxia;   Polyneuropathy - Hearing Loss - Ataxia - Retinitis Pigmentosa - Cataract;   Muscular Atrophy - Ataxia - Retinitis Pigmentosa - Diabetes Mellitus;   Non-progressive Cerebellar Ataxia With Intellectual Disability;   Non-hereditary Degenerative Ataxia;   Paroxysmal Dystonic Choreathetosis With Episodic Ataxia and Spasticity;   Olivopontocerebellar Atrophy - Deafness;   NARP Syndrome;   Myoclonus - Cerebellar Ataxia - Deafness;   Multiple System Atrophy, Parkinsonian Type;   Multiple System Atrophy, Cerebellar Type;   Multiple System Atrophy;   Maternally-inherited Leigh Syndrome;   Machado-Joseph Disease Type 3;   Machado-Joseph Disease Type 2;   Machado-Joseph Disease Type 1;   Lethal Ataxia With Deafness and Optic Atrophy;   Leigh Syndrome;   Leukoencephalopathy With Mild Cerebellar Ataxia and White Matter Edema;   Leukoencephalopathy - Ataxia - Hypodontia - Hypomyelination;   Leigh Syndrome With Nephrotic Syndrome;   Leigh Syndrome With Leukodystrophy;   Leigh Syndrome With Cardiomyopathy;   Late-onset Ataxia With Dementia;   Intellectual Disability-hyperkinetic Movement-truncal Ataxia Syndrome;   Infection or Post Infection Ataxia;   Infantile-onset Autosomal Recessive Nonprogressive Cerebellar Ataxia;   Infantile Onset Spinocerebellar Ataxia;   GAD Ataxia;   Hereditary Episodic Ataxia;   Gliadin/Gluten Ataxia;   Friedreich Ataxia;   Fragile X-associated Tremor/Ataxia Syndrome;   Familial Paroxysmal Ataxia;   Exposure to Medications Ataxia;   Episodic Ataxia With Slurred Speech;   Episodic Ataxia Unknown Type;   Episodic Ataxia Type 7;   Episodic Ataxia Type 6;   Episodic Ataxia Type 5;   Episodic Ataxia Type 4;   Episodic Ataxia Type 3;   Episodic Ataxia Type 1;   Epilepsy and/or Ataxia With Myoclonus as Major Feature;   Early-onset Spastic Ataxia-neuropathy Syndrome;   Early-onset Progressive Neurodegeneration - Blindness - Ataxia - Spasticity;   Early-onset Cerebellar Ataxia With Retained Tendon Reflexes;   Early-onset Ataxia With Dementia;   Childhood-onset Autosomal Recessive Slowly Progressive Spinocerebellar Ataxia;   Dilated Cardiomyopathy With Ataxia;   Cataract - Ataxia - Deafness;   Cerebellar Ataxia, Cayman Type;   Cerebellar Ataxia With Peripheral Neuropathy;   Cerebellar Ataxia - Hypogonadism;   Cerebellar Ataxia - Ectodermal Dysplasia;   Cerebellar Ataxia - Areflexia - Pes Cavus - Optic Atrophy - Sensorineural Hearing Loss;   Brain Tumor Ataxia;   Brachydactyly - Nystagmus - Cerebellar Ataxia;   Benign Paroxysmal Tonic Upgaze of Childhood With Ataxia;   Autosomal Recessive Syndromic Cerebellar Ataxia;   Autosomal Recessive Spastic Ataxia With Leukoencephalopathy;   Autosomal Recessive Spastic Ataxia of Charlevoix-Saguenay;   Autosomal Recessive Spastic Ataxia - Optic Atrophy - Dysarthria;   Autosomal Recessive Spastic Ataxia;   Autosomal Recessive Metabolic Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to Repeat Expansions That do Not Encode Polyglutamine;   Autosomal Recessive Ataxia, Beauce Type;   Autosomal Recessive Ataxia Due to Ubiquinone Deficiency;   Autosomal Recessive Ataxia Due to PEX10 Deficiency;   Autosomal Recessive Degenerative and Progressive Cerebellar Ataxia;   Autosomal Recessive Congenital Cerebellar Ataxia Due to MGLUR1 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia Due to GRID2 Deficiency;   Autosomal Recessive Congenital Cerebellar Ataxia;   Autosomal Recessive Cerebellar Ataxia-pyramidal Signs-nystagmus-oculomotor Apraxia Syndrome;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to WWOX Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to TUD Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome Due to KIAA0226 Deficiency;   Autosomal Recessive Cerebellar Ataxia-epilepsy-intellectual Disability Syndrome;   Autosomal Recessive Cerebellar Ataxia With Late-onset Spasticity;   Autosomal Recessive Cerebellar Ataxia Due to STUB1 Deficiency;   Autosomal Recessive Cerebellar Ataxia Due to a DNA Repair Defect;   Autosomal Recessive Cerebellar Ataxia - Saccadic Intrusion;   Autosomal Recessive Cerebellar Ataxia - Psychomotor Retardation;   Autosomal Recessive Cerebellar Ataxia - Blindness - Deafness;   Autosomal Recessive Cerebellar Ataxia;   Autosomal Dominant Spinocerebellar Ataxia Due to a Polyglutamine Anomaly;   Autosomal Dominant Spinocerebellar Ataxia Due to a Point Mutation;   Autosomal Dominant Spinocerebellar Ataxia Due to a Channelopathy;   Autosomal Dominant Spastic Ataxia Type 1;   Autosomal Dominant Spastic Ataxia;   Autosomal Dominant Optic Atrophy;   Ataxia-telangiectasia Variant;   Ataxia-telangiectasia;   Autosomal Dominant Cerebellar Ataxia, Deafness and Narcolepsy;   Autosomal Dominant Cerebellar Ataxia Type 4;   Autosomal Dominant Cerebellar Ataxia Type 3;   Autosomal Dominant Cerebellar Ataxia Type 2;   Autosomal Dominant Cerebellar Ataxia Type 1;   Autosomal Dominant Cerebellar Ataxia;   Ataxia-telangiectasia-like Disorder;   Ataxia-intellectual Disability-oculomotor Apraxia-cerebellar Cysts Syndrome;   Ataxia-deafness-intellectual Disability Syndrome;   Ataxia With Vitamin E Deficiency;   Ataxia With Dementia;   Ataxia Neuropathy Spectrum;   Ataxia - Tapetoretinal Degeneration;   Ataxia - Photosensitivity - Short Stature;   Ataxia - Pancytopenia;   Ataxia - Oculomotor Apraxia Type 1;   Ataxia - Hypogonadism - Choroidal Dystrophy;   Ataxia - Other;   Ataxia - Genetic Diagnosis - Unknown;   Acquired Ataxia;   Adult-onset Autosomal Recessive Cerebellar Ataxia;   Alcohol Related Ataxia;   Multiple Endocrine Neoplasia;   Multiple Endocrine Neoplasia Type II;   Multiple Endocrine Neoplasia Type 1;   Multiple Endocrine Neoplasia Type 2;   Multiple Endocrine Neoplasia, Type IV;   Multiple Endocrine Neoplasia, Type 3;   Multiple Endocrine Neoplasia (MEN) Syndrome;   Multiple Endocrine Neoplasia Type 2B;   Multiple Endocrine Neoplasia Type 2A;   Atypical Hemolytic Uremic Syndrome;   Atypical HUS;   Wiedemann-Steiner Syndrome;   Breast Implant-Associated Anaplastic Large Cell Lymphoma;   Autoimmune/Inflammatory Syndrome Induced by Adjuvants (ASIA);   Hemophagocytic Lymphohistiocytosis;   Behcet's Disease;   Alagille Syndrome;   Inclusion Body Myopathy With Early-onset Paget Disease and Frontotemporal Dementia (IBMPFD);   Lowe Syndrome;   Pitt Hopkins Syndrome;   1p36 Deletion Syndrome;   Jansen Type Metaphyseal Chondrodysplasia;   Cockayne Syndrome;   Chronic Recurrent Multifocal Osteomyelitis;   CRMO;   Malan Syndrome;   Hereditary Sensory and Autonomic Neuropathy Type Ie
    Intervention:  
    Sponsors:   Sanford Health;   National Ataxia Foundation;   International WAGR Syndrome Association;   4p- Support Group;   ML4 Foundation;   Cornelia de Lange Syndrome Foundation;   Stickler Involved People;   Kawasaki Disease Foundation;   Klippel-Feil Syndrome Alliance;   Klippel-Feil Syndrome Freedom;   Hyperacusis Research Limited;   Hypersomnia Foundation;   Kabuki Syndrome Network;   Kleine-Levin Syndrome Foundation;   Leiomyosarcoma Direct Research Foundation;   Marinesco-Sjogren Syndrome Support Group;   Mucolipidosis Type IV (ML4) Foundation;   People with Narcolepsy 4 People with Narcolepsy (PWN4PWN);   Soft Bones Incorporated;   American Multiple Endocrine Neoplasia Support;   Atypical Hemolytic Uremic Syndrome Foundation;   All Things Kabuki;   Wiedemann-Steiner Syndrome Foundation;   Breast Implant Victim Advocates;   PROS Foundation;   American Behcet's Disease Association
    Recruiting

  • Conditions:   Risk-directed Therapy;   Cytogenetic Abnormality;   Molecular Abnormality;   MRD
    Intervention:   Other: Justified risk stratification based on MRD after two course induction
    Sponsors:   Nanfang Hospital of Southern Medical University;   Second Affiliated Hospital, Sun Yat-Sen University;   Third Affiliated Hospital, Sun Yat-Sen University;   Guangzhou First People's Hospital;   Wuhan General Hospital of Guangzhou Military Command;   Shenzhen Hospital of Southern Medical University;   Peking University Shenzhen Hospital;   Shenzhen Second People's Hospital;   Zhongshan People's Hospital, Guangdong, China;   First Affiliated Hospital of Guangxi Medical University;   Xiangya Hospital of Central South University;   The Third Xiangya Hospital of Central South University;   First Affiliated Hospital of Gannan Medical University;   Peking University People's Hospital;   Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine;   The First Affiliated Hospital of Zhengzhou University;   Chenzhou NO. 1 people's Hospital
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   CD19 Positive;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Refractory Acute Lymphoblastic Leukemia
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Crystal Mackall, MD;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Phelan-McDermid Syndrome;   Epilepsy
    Intervention:   Drug: AMO-01
    Sponsor:   Alexander Kolevzon
    Recruiting

  • Conditions:   XXY (Klinefelter);   Sex Chromosome Variation;   Sex Chromosome Aneuploidy;   XXXY;   XXXXXY;   XYY (Jacob);   XXYY;   X (XO, Turner);   XXX (Trisomy X, Triple X);   XXXX (Tetrasomy X);   XXXXX (Pentasomy X)
    Intervention:  
    Sponsor:   National Institute of Mental Health (NIMH)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Blasts 10 Percent or More of Bone Marrow Nucleated Cells;   High Risk Myelodysplastic Syndrome;   Myeloid Sarcoma;   Myeloproliferative Neoplasm;   Philadelphia Chromosome Positive
    Interventions:   Drug: Cladribine;   Drug: Cytarabine;   Drug: Dexrazoxane Hydrochloride;   Drug: Gemtuzumab Ozogamicin;   Drug: Idarubicin
    Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blasts 20 Percent or More of Bone Marrow Nucleated Cells;   Blasts 5-19 Percent of Bone Marrow Nucleated Cells;   Blasts More Than 5 Percent of Bone Marrow Nucleated Cells;   Chronic Myelomonocytic Leukemia;   Essential Thrombocythemia;   Myelodysplastic/Myeloproliferative Neoplasm;   Myelofibrosis;   Philadelphia Chromosome Negative;   Polycythemia Vera;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Acute Myeloid Leukemia
    Interventions:   Drug: Carboplatin;   Drug: Topotecan;   Drug: Topotecan Hydrochloride;   Drug: Veliparib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   CD19 Positive;   Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation;   Diffuse Large B-Cell Lymphoma, Not Otherwise Specified;   Epstein-Barr Virus Positive Diffuse Large B-Cell Lymphoma of the Elderly;   Minimal Residual Disease;   Philadelphia Chromosome Positive;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mediastinal (Thymic) Large B-Cell Cell Lymphoma;   T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
    Interventions:   Biological: Chimeric Antigen Receptor T-Cell Therapy;   Drug: Cyclophosphamide;   Drug: Fludarabine Phosphate;   Other: Laboratory Biomarker Analysis;   Other: Questionnaire Administration
    Sponsors:   Crystal Mackall, MD;   California Institute for Regenerative Medicine (CIRM)
    Recruiting

  • Condition:   Recurrent Implantation Failure
    Interventions:   Procedure: PGT-A;   Procedure: Control
    Sponsor:   Universitaire Ziekenhuizen Leuven
    Not yet recruiting

  • Condition:   Soft Markers
    Interventions:   Device: Midtrimester anomaly scan;   Genetic: Fetal Karyotyping
    Sponsor:   Cairo University
    Recruiting

  • Condition:   Aneuploidy
    Intervention:   Other: Non intervention
    Sponsor:   IVI Barcelona
    Recruiting

  • Conditions:   Prenatal Disorder;   Aneuploidy
    Interventions:   Diagnostic Test: Traditional integrated prenatal screening;   Diagnostic Test: Second-tier Non-invasive prenatal screening (NIPS);   Diagnostic Test: First-tier Non-invasive prenatal screening (NIPS);   Diagnostic Test: Invasive prenatal testing for fetal aneuploidy
    Sponsors:   CHU de Quebec-Universite Laval;   Genome Quebec;   Genome British Columbia;   Genome Alberta;   Ontario Research Fund;   Laval University;   St. Justine's Hospital;   Ottawa Hospital Research Institute;   McGill University;   University of British Columbia;   University of Alberta;   Genome Canada;   Canadian Institutes of Health Research (CIHR)
    Not yet recruiting

  • Conditions:   Aneuploidy;   Birth Defect
    Intervention:   Other: video
    Sponsors:   University of South Florida;   Tampa General Hospital
    Not yet recruiting

  • Conditions:   Epilepsy; Seizure;   Neuromuscular Diseases;   Brain Malformation;   Intellectual Disability;   Autism Spectrum Disorder;   Hypotonia;   Inborn Errors of Metabolism;   Movement Disorders;   Genetic Disease;   Development Delay;   Chromosome Abnormality;   Hearing Loss;   Dysmorphic Features;   Skeletal Dysplasia;   Congenital Abnormality;   Microcephaly;   Macrocephaly
    Interventions:   Behavioral: Pre-visit prep;   Diagnostic Test: usual care + exome seq
    Sponsors:   University of North Carolina, Chapel Hill;   National Human Genome Research Institute (NHGRI);   East Carolina University;   Mission Health System, Asheville, NC
    Recruiting

  • Condition:   Euploid Embryos
    Intervention:  
    Sponsor:   Instituto Valenciano de Infertilidad, IVI VALENCIA
    Recruiting

  • Conditions:   Microdeletion 3q29 Syndrome;   Microduplication 3q29 Syndrome
    Intervention:  
    Sponsor:   Emory University
    Recruiting

  • Condition:   Infertility
    Intervention:   Other: Comprehensive Chromosomal Screening
    Sponsor:   Reproductive Medicine Associates of New Jersey
    Recruiting

  • Conditions:   Phelan-McDermid Syndrome;   Autism Spectrum Disorder;   Intellectual Disability
    Intervention:   Other: No Intervention
    Sponsors:   Boston Children’s Hospital;   Phelan-McDermid Syndrome Foundation
    Recruiting

  • Condition:   Klinefelter Syndrome
    Interventions:   Drug: Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution;   Drug: Placebo injectable saline
    Sponsors:   University of Colorado, Denver;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Multiple Myeloma;   Plasma Cell Leukemia;   Extramedullary Plasmacytoma;   Loss of Chromosome 17p;   t(14;16);   t(4;14);   T(14;20);   1Q21 Amplification;   Complex Karyotype
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Procedure: Autologous Hematopoietic Stem Cell Transplantation x 1 or x 2;   Drug: Melphalan Given IV;   Drug: Fludarabine Injection;   Drug: PI and dexamethasone as maintenance therapy;   Drug: PI+IMids+Dexamethasone as Consolidated Chemotherapy
    Sponsor:   Institute of Hematology & Blood Diseases Hospital
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia in Remission;   Hematopoietic Cell Transplantation Recipient;   JAK2 Gene Mutation;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Minimal Residual Disease;   Myelodysplastic Syndrome;   Non-Hodgkin Lymphoma;   Plasma Cell Myeloma;   RAS Family Gene Mutation;   Recurrent Diffuse Large B-Cell Lymphoma;   Recurrent Hematologic Malignancy;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Refractory Diffuse Large B-Cell Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma;   Therapy-Related Acute Myeloid Leukemia;   Therapy-Related Myelodysplastic Syndrome;   TP53 Gene Mutation
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Biological: Irradiated Allogeneic Cells
    Sponsors:   Rutgers, The State University of New Jersey;   National Cancer Institute (NCI)
    Not yet recruiting

  • Conditions:   Chronic Lymphocytic Leukemia;   Richter Syndrome;   Diffuse Large B Cell Lymphoma;   Follicular Lymphoma;   Indolent Non-hodgkin Lymphoma;   Loss of Chromosome 17p;   Lymphoplasmacytic Lymphoma;   Marginal Zone Lymphoma;   TP53 Gene Mutation
    Interventions:   Drug: Copanlisib;   Biological: Nivolumab
    Sponsors:   OHSU Knight Cancer Institute;   Oregon Health and Science University;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Acute Lymphoblastic Leukemia;   Acute Myeloid Leukemia;   Aggressive Non-Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia;   Diffuse Large B-Cell Lymphoma;   Hematopoietic Cell Transplant Recipient;   Loss of Chromosome 17p;   Mantle Cell Lymphoma;   Myelodysplastic Syndrome;   Myelodysplastic/Myeloproliferative Neoplasm;   Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive;   Recurrent Hodgkin Lymphoma;   Recurrent Plasma Cell Myeloma;   Recurrent Small Lymphocytic Lymphoma;   Recurrent Waldenstrom Macroglobulinemia
    Interventions:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Drug: Mycophenolate Mofetil;   Drug: Sirolimus
    Sponsors:   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting

  • Conditions:   Anaplastic Astrocytoma;   Anaplastic Ependymoma;   Anaplastic Ganglioglioma;   Anaplastic Meningioma;   Anaplastic Oligodendroglioma;   Pleomorphic Xanthoastrocytoma, Anaplastic;   Atypical Teratoid/Rhabdoid Tumor;   Brain Cancer;   Brain Tumor;   Central Nervous System Neoplasms;   Choroid Plexus Carcinoma;   CNS Embryonal Tumor With Rhabdoid Features;   Ganglioneuroblastoma of Central Nervous System;   CNS Tumor;   Embryonal Tumor of CNS;   Ependymoma;   Glioblastoma;   Glioma;   Glioma, Malignant;   Medulloblastoma;   Medulloblastoma; Unspecified Site;   Medulloepithelioma;   Neuroepithelial Tumor;   Neoplasms;   Neoplasms, Neuroepithelial;   Papillary Tumor of the Pineal Region (High-grade Only);   Pediatric Brain Tumor;   Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only);   Pineoblastoma;   Primitive Neuroectodermal Tumor;   Recurrent Medulloblastoma;   Refractory Brain Tumor;   Neuroblastoma. CNS;   Glioblastoma, IDH-mutant;   Glioblastoma, IDH-wildtype;   Medulloblastoma, Group 3;   Medulloblastoma, Group 4;   Glioma, High Grade;   Neuroepithelial Tumor, High Grade;   Medulloblastoma, SHH-activated and TP53 Mutant;   Medulloblastoma, SHH-activated and TP53 Wildtype;   Medulloblastoma, Chromosome 9q Loss;   Medulloblastoma, Non-WNT Non-SHH, NOS;   Medulloblastoma, Non-WNT/Non-SHH;   Medulloblastoma, PTCH1 Mutation;   Medulloblastoma, WNT-activated;   Ependymoma, Recurrent;   Glioma, Recurrent High Grade;   Glioma, Recurrent Malignant;   Embryonal Tumor, NOS;   Glioma, Diffuse Midline, H3K27M-mutant;   Embryonal Tumor With Multilayered Rosettes (ETMR);   Ependymoma, NOS, WHO Grade III;   Ependymoma, NOS, WHO Grade II;   Medulloblastoma, G3/G4;   Ependymoma, RELA Fusion Positive
    Interventions:   Drug: Gemcitabine;   Drug: ribociclib;   Drug: sonidegib;   Drug: trametinib;   Biological: filgrastim
    Sponsors:   St. Jude Children's Research Hospital;   Novartis Pharmaceuticals
    Recruiting

  • Conditions:   Infertility;   Aneuploidy
    Intervention:   Procedure: Laser Acupuncture
    Sponsor:   University of British Columbia
    Not yet recruiting

  • Condition:   Chronic Myelomonocytic Leukemia
    Intervention:  
    Sponsor:   University of Arkansas
    Recruiting

  • Condition:   Smith Magenis Syndrome
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting

  • Condition:   Pregnancy
    Intervention:   Diagnostic Test: cfDNA screening
    Sponsor:   University Hospital Tuebingen
    Recruiting

  • Condition:   Down Syndrome, Trisomy 21
    Interventions:   Other: CO-OP;   Other: Conductive Education
    Sponsor:   Hülya Özbeşer
    Recruiting

  • Condition:   Down Syndrome, Trisomy 21
    Intervention:   Behavioral: JASPER
    Sponsor:   Boston Children’s Hospital
    Recruiting

  • Conditions:   Down Syndrome;   Trisomy 21
    Intervention:   Behavioral: Watching a video
    Sponsor:   Advocate Health Care
    Recruiting

  • Conditions:   Down Syndrome;   Trisomy 21
    Intervention:  
    Sponsors:   University of Colorado, Denver;   Linda Crnic Institute for Down Syndrome
    Recruiting

  • Conditions:   Acute Myeloid Leukemia;   Blasts 5 Percent or More of Bone Marrow Nucleated Cells;   Cytopenia;   Down Syndrome;   Myelodysplastic Syndrome;   Myeloid Leukemia Associated With Down Syndrome;   Myeloproliferative Neoplasm;   Trisomy 21;   Trisomy 21 Mosaicism
    Interventions:   Drug: Asparaginase;   Drug: Asparaginase Erwinia chrysanthemi;   Drug: Cytarabine;   Drug: Daunorubicin Hydrochloride;   Drug: Etoposide;   Other: Laboratory Biomarker Analysis;   Drug: Mitoxantrone Hydrochloride;   Drug: Thioguanine
    Sponsors:   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Primary Ovarian Insufficiency
    Intervention:   Genetic: Cell therapy
    Sponsors:   Chinese Academy of Sciences;   The First Affiliated Hospital of Zhengzhou University;   National Natural Science Foundation of China
    Recruiting

  • Conditions:   Turner Syndrome;   Isolated Growth Hormone Deficiency;   Cognitive Functions;   Social Cognition;   Pediatrics
    Intervention:   Behavioral: psychological evaluation
    Sponsors:   University Hospital, Angers;   University of Angers, Angers
    Not yet recruiting

  • Condition:   Down Syndrome
    Intervention:   Genetic: karyotype
    Sponsor:   University Hospital, Strasbourg, France
    Recruiting

  • Condition:   Primary Ovarian Insufficiency
    Intervention:   Drug: Transdermal Estrogen
    Sponsor:   Children's Hospital Medical Center, Cincinnati
    Recruiting

  • Condition:   Turner Syndrome
    Intervention:   Behavioral: ANS training
    Sponsor:   Stanford University
    Not yet recruiting

  • Conditions:   Primary Ovarian Insufficiency;   Female Infertility
    Intervention:   Procedure: Ovarian tissue transplant
    Sponsor:   University of Pittsburgh
    Recruiting

  • Conditions:   Premature Ovarian Failure;   Primary Ovarian Insufficiency;   Ovarian Dysgenesis;   Diminished Ovarian Reserve
    Intervention:   Procedure: IVF treatment
    Sponsors:   The First Affiliated Hospital of Anhui Medical University;   National Research Institute for Family Planning, China
    Recruiting

  • Condition:   Turner Syndrome
    Intervention:   Genetic: Research genetic tests
    Sponsors:   The University of Texas Health Science Center, Houston;   American Heart Association
    Recruiting

  • Conditions:   Primary Ovarian Insufficiency;   Low Ovarian Reserve;   Premature Ovarian Failure
    Intervention:   Procedure: ROSE-1 Protocol
    Sponsor:   University of Illinois at Chicago
    Recruiting

  • Conditions:   Down Syndrome;   Edwards Syndrome;   Patau Syndrome;   Klinefelter Syndrome;   Turner Syndrome;   DiGeorge Syndrome;   Perinatal Infections
    Intervention:   Other: Observational - no intervention
    Sponsor:   Progenity, Inc.
    Recruiting

  • Conditions:   Cystic Fibrosis;   Immunologic Deficiency Syndrome;   Turner Syndrome;   Congenital Hepatic Fibrosis;   Idiopathic Non-Cirrhotic Portal Hypertension
    Intervention:  
    Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Turner Syndrome;   Peripheral Angiopathy;   Vascular Malformation;   Lymphedema
    Intervention:   Procedure: Echo doppler
    Sponsor:   University Hospital, Strasbourg, France
    Recruiting

  • Condition:   Fragile X Syndrome
    Intervention:   Drug: ZYN002 - CBD Transdermal Gel
    Sponsor:   Zynerba Pharmaceuticals, Inc.
    Recruiting

  • Condition:   Fragile X Syndrome
    Intervention:   Drug: Metformin
    Sponsors:   Université de Sherbrooke;   FRAXA Research Foundation
    Recruiting

  • Condition:   Fragile X Syndrome (FXS)
    Intervention:   Drug: OV101 (gaboxadol)
    Sponsor:   Ovid Therapeutics Inc.
    Recruiting

  • Condition:   Fragile X Syndrome
    Interventions:   Drug: ZYN002 - CBD Transdermal Gel;   Other: Placebo Transdermal Gel
    Sponsor:   Zynerba Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Fragile X Syndrome;   Disruptive Behavior
    Intervention:   Behavioral: Behavior analytic treatment
    Sponsors:   Stanford University;   The John Merck Fund
    Recruiting

  • Condition:   Fragile X Syndrome
    Interventions:   Drug: AFQ056;   Other: Placebo;   Other: Language Intervention
    Sponsors:   Elizabeth Berry-Kravis;   National Institute of Neurological Disorders and Stroke (NINDS)
    Recruiting

  • Conditions:   Genetic Disorder;   Asperger Disorder;   Autism Spectrum Disorder;   Fragile X Syndrome;   Developmental Delay
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Fragile X Syndrome;   Intellectual Disability
    Intervention:   Behavioral: Social gaze training
    Sponsor:   Stanford University
    Recruiting

  • Conditions:   Hepato/Renal Fibrocystic Disease;   Autosomal Recessive Polycystic Kidney Disease;   Joubert Syndrome;   Bardet Biedl Syndrome;   Meckel-Gruber Syndrome;   Congenital Hepatic Fibrosis;   Caroli Syndrome;   Oro-Facial-Digital Syndrome Type I;   Nephronophthisis;   Glomerulocystic Kidney Disease
    Intervention:  
    Sponsors:   Lisa M. Guay-Woodford;   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting

  • Conditions:   Velocardiofacial Syndrome;   Williams Syndrome;   Fragile X Syndrome
    Intervention:   Drug: methylphenidate, fluoxetin, risperidone
    Sponsor:   The Chaim Sheba Medical Center
    Recruiting

  • Conditions:   Fragile X Syndrome;   Healthy Volunteers
    Intervention:  
    Sponsor:   National Institute of Mental Health (NIMH)
    Recruiting

  • Conditions:   16p11.2 Deletions;   16p11.2 Duplications;   1q21.1 Deletions;   1q21.1 Duplications;   ACTL6B;   ADNP;   AHDC1;   ANK2;   ANKRD11;   ARID1B;   ASH1L;   ASXL3;   BCL11A;   CHAMP1;   CHD2;   CHD8;   CSNK2A1;   CTBP1;   CTNNB1;   CUL3;   DDX3X;   DNMT3A;   DSCAM;   DST;   DYRK1A;   FOXP1;   GRIN2A;   GRIN2B;   HIVEP2;   HNRNPH2;   KAT6A;   KATNAL2;   KDM5B;   KDM6B;   KMT2C;   KMT2E;   KMT5B (Previously SUV420H1);   MBD5;   MED13L;   PACS1;   PBRM1;   POGZ;   PPP2R5D;   PTCHD1;   PTEN;   PURA;   REST;   SCN2A;   SETBP1;   SETD5;   SMARCA4 (BAF190);   SMARCC1;   SMARCC2;   STXBP1;   SYNGAP1;   TBR1;   Additional Genetic Changes Associated With Autism May be Added as Identified;   ARHGEF9;   HNRNPU;   KCNQ2;   PPP2B;   PPP2R1A;   SLC6A1
    Intervention:  
    Sponsors:   Simons Searchlight;   Geisinger Clinic;   Columbia University;   TEMPUS;   Harvard University;   Baylor University;   University of Washington;   University of California, San Francisco;   Children's Hospital of Philadelphia;   Simons Foundation
    Recruiting

  • Conditions:   Acute Lymphoid Leukemia;   B-Cell Leukemia;   Leukemia, Lymphocytic, B Cell;   B-Cell Lymphoma;   Lymphoma, Non-Hodgkin
    Interventions:   Biological: CD19/CD22 CAR T-Cells;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Non-small Cell Lung Cancer
    Interventions:   Procedure: Biopsy of the major carinal area;   Procedure: Biopsy of abnormal & suspicious areas of the bronchial tree;   Procedure: Evaluation of the tumor for DNA mutations;   Procedure: Bronchoalveolar Lavage (BAL) for cytokine analysis;   Procedure: Correlation of flow cytometric & RT PCR for TNM stage;   Procedure: Analysis of lymph nodes
    Sponsors:   University of Pittsburgh;   National Institutes of Health (NIH)
    Recruiting

  • Condition:   Neoplasm
    Intervention:   Drug: Crizotinib
    Sponsor:   Pfizer
    Available

  • Conditions:   Adolescent Behavior;   Intellectual Disability;   Down Syndrome;   Physical Activity
    Interventions:   Behavioral: Group Exercise Sessions;   Behavioral: Individual Support Sessions;   Behavioral: Facebook Group
    Sponsors:   University of Kansas;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Condition:   Down Syndrome
    Intervention:   Behavioral: Speech therapy addressing phonology and motor learning
    Sponsors:   University of Wisconsin, Madison;   Office of the Vice Chancellor for Research and Graduate Education;   Wisconsin Alumni Research Foundation
    Not yet recruiting

  • Conditions:   Williams-Beuren Syndrome;   Micro-duplication 7q11.23 Syndrome;   Vasculopathy
    Interventions:   Biological: Physical examination and Urine and blood samples;   Biological: Urine and blood samples
    Sponsor:   Hospices Civils de Lyon
    Not yet recruiting

  • Conditions:   Down Syndrome;   Alzheimer Disease
    Interventions:   Behavioral: Remote Low;   Behavioral: Remote High;   Behavioral: Personal Coach
    Sponsors:   University of Kansas Medical Center;   National Institute on Aging (NIA)
    Not yet recruiting

  • Conditions:   Down Syndrome;   Social Skills;   Physical Activity
    Intervention:   Other: Survey
    Sponsor:   Universidad de Córdoba
    Not yet recruiting

  • Condition:   Prader-Willi Syndrome
    Intervention:  
    Sponsors:   The Hospital for Sick Children;   Holland Bloorview Kids Rehabilitation Hospital;   University of Western Ontario, Canada
    Recruiting

  • Conditions:   Down Syndrome;   Obstructive Sleep Apnea;   Child
    Interventions:   Diagnostic Test: Video clip assessment;   Diagnostic Test: Polysomnography (sleep study);   Other: Educational webinar
    Sponsors:   Children's Hospital of Eastern Ontario;   The Physicians' Services Incorporated Foundation
    Not yet recruiting

  • Conditions:   Intellectual Disability;   Down Syndrome
    Intervention:   Behavioral: Self-monitoring shopping intervention
    Sponsor:   Columbia University
    Recruiting

  • Conditions:   Alzheimer's Disease;   Obstructive Sleep Apnea;   Sleep Disturbances
    Intervention:  
    Sponsor:   Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
    Recruiting

  • Condition:   Down Syndrome
    Intervention:   Behavioral: Enhanced Milieu teaching
    Sponsor:   Oregon Health and Science University
    Recruiting

  • Conditions:   Down Syndrome;   Sleep Disordered Breathing
    Intervention:   Procedure: Adenotonsillectomy
    Sponsors:   Brigham and Women's Hospital;   Children's Hospital of Philadelphia;   University Hospitals Cleveland Medical Center;   Children's Hospital Medical Center, Cincinnati;   University of Michigan;   University of Texas Southwestern Medical Center;   University of Rochester;   Children's Hospital of The King's Daughters
    Recruiting

  • Conditions:   B Acute Lymphoblastic Leukemia;   B Lymphoblastic Lymphoma;   Blasts More Than 25 Percent of Bone Marrow Nucleated Cells;   Down Syndrome
    Interventions:   Drug: Asparaginase Erwinia chrysanthemi;   Biological: Blinatumomab;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Doxorubicin;   Drug: Doxorubicin Hydrochloride;   Drug: Leucovorin;   Drug: Leucovorin Calcium;   Drug: Mercaptopurine;   Drug: Mercaptopurine Oral Suspension;   Drug: Methotrexate;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Thioguanine;   Drug: Vincristine;   Drug: Vincristine Sulfate
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Down Syndrome
    Intervention:   Other: Nocturnal gaz exchanges measurement
    Sponsors:   Institut Jerome Lejeune;   Hôpital Armand Trousseau
    Not yet recruiting

  • Conditions:   Down Syndrome;   Alzheimer Disease
    Intervention:   Procedure: Neuro-imaging, Lumbar puncture
    Sponsor:   Institut Jerome Lejeune
    Recruiting

  • Condition:   Angelman Syndrome
    Intervention:   Drug: OV101
    Sponsor:   Ovid Therapeutics Inc.
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Intervention:   Behavioral: Safe and Sound Protocol
    Sponsors:   Indiana University;   Integrated Listening Systems
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Intervention:   Other: Hippotherapy
    Sponsors:   Samsung Medical Center;   Samsung Electronics
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Interventions:   Drug: CBDV Compound;   Drug: Placebo
    Sponsors:   Montefiore Medical Center;   Foundation for Prader-Willi Research
    Not yet recruiting

  • Condition:   Prader-Willi Syndrome
    Interventions:   Dietary Supplement: Coenzyme Q10;   Other: Placebo
    Sponsors:   The Hospital for Sick Children;   Foundation for Prader-Willi Research
    Not yet recruiting

  • Conditions:   Williams Syndrome;   Anxiety
    Intervention:   Behavioral: Cognitive and Behavioral Therapy
    Sponsors:   University Hospital, Montpellier;   Fondation Jérôme Lejeune;   association autour des Williams;   réseau de santé Maladies Rares
    Not yet recruiting

  • Conditions:   Prader-Willi Syndrome;   Hyperphagia
    Interventions:   Drug: Livoletide;   Drug: Placebo
    Sponsor:   Millendo Therapeutics SAS
    Recruiting

  • Conditions:   Cataract;   Down Syndrome
    Intervention:   Procedure: cataract surgery
    Sponsors:   University of Colorado, Denver;   Children's Hospital Colorado
    Recruiting

  • Conditions:   Obstructive Sleep Apnea;   Down Syndrome
    Intervention:   Diagnostic Test: Sleep study
    Sponsor:   Oregon Health and Science University
    Recruiting

  • Conditions:   Down Syndrome;   Augmentative and Alternative Communication
    Interventions:   Device: AAC Technology - Standard of Care;   Device: AAC Technology - non-optimal integrated arrangement
    Sponsors:   Penn State University;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Williams Syndrome;   Lipedema
    Intervention:  
    Sponsors:   Massachusetts General Hospital;   Lipedema Foundation;   Williams Syndrome Association
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Intervention:  
    Sponsors:   Zafgen, Inc.;   Foundation for Prader-Willi Research
    Recruiting

  • Conditions:   Electromyography;   EMG: Myopathy;   EMG Syndrome;   Pelvic Pain;   Pelvic Floor Disorders;   Pelvic Pain Syndrome;   ElectroPhys: Myopathy
    Intervention:   Drug: Clostridium botulinum type A (BoNTA)
    Sponsor:   Jose Alberola-Rubio
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Intervention:   Drug: DCCR
    Sponsor:   Soleno Therapeutics, Inc.
    Recruiting

  • Conditions:   Stuttering;   Down Syndrome
    Intervention:   Behavioral: hand gestures
    Sponsors:   Universitaire Ziekenhuizen Leuven;   Marguerite-Marie Delacroix;   KU Leuven
    Not yet recruiting

  • Condition:   Mental Disorders
    Interventions:   Behavioral: Manipulation of valence and modality;   Behavioral: Spatial and recognition memory;   Behavioral: Source and content memory
    Sponsor:   Hôpital le Vinatier
    Recruiting

  • Condition:   Angelman Syndrome
    Intervention:  
    Sponsor:   Fondazione per la Ricerca Ospedale Maggiore
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Interventions:   Drug: intranasal carbetocin Dose 1;   Drug: intranasal carbetocin Dose 2;   Drug: placebo
    Sponsor:   Levo Therapeutics, Inc.
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Intervention:   Drug: Cannabidiol Oral Solution
    Sponsor:   INSYS Therapeutics Inc
    Recruiting

  • Conditions:   Down Syndrome;   Sleep Apnea, Obstructive;   Polysomnography
    Intervention:   Diagnostic Test: Assessment of OSAS predictive factors
    Sponsor:   University Hospital, Grenoble
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Interventions:   Drug: DCCR;   Drug: Placebo for DCCR
    Sponsor:   Soleno Therapeutics, Inc.
    Recruiting

  • Condition:   Congenital Heart Disease
    Intervention:   Other: Blood Sample Collection
    Sponsors:   Nationwide Children's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   22q11.2 Deletion Syndrome
    Intervention:   Behavioral: Cognitive remediation program
    Sponsor:   Hôpital le Vinatier
    Recruiting

  • Conditions:   Down Syndrome;   Obstructive Sleep Apnea of Newborn
    Intervention:   Diagnostic Test: Polysomnography (PSG)
    Sponsors:   Institut Jerome Lejeune;   Hôpital Necker-Enfants Malades
    Recruiting

  • Conditions:   Prader-Willi Syndrome;   Hyperphagia
    Interventions:   Drug: Intranasal Oxytocin (IN-OXT);   Drug: Matched Placebo
    Sponsor:   Montefiore Medical Center
    Recruiting

  • Condition:   Confirmed Genetic Diagnosis of Prader-Willi Syndrome
    Interventions:   Drug: Tesofensine/Metoprolol;   Drug: Placebos
    Sponsor:   Saniona
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Interventions:   Drug: Oxytocin;   Drug: Placebo
    Sponsor:   University Hospital, Toulouse
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Intervention:   Behavioral: Listening Project Protocol
    Sponsors:   Indiana University;   Latham Centers
    Recruiting

  • Conditions:   Sleep Apnea, Central;   Prader-Willi Syndrome
    Intervention:   Biological: Medical Air vs Oxygen
    Sponsor:   The Hospital for Sick Children
    Recruiting

  • Conditions:   Pro-opiomelanocortin (POMC) Deficiency Obesity (Heterozygous or Epigenetic);   Leptin Receptor Deficiency Obesity;   Bardet-Biedl Syndrome;   Alstrom Syndrome;   Smith-Magenis Syndrome
    Intervention:   Drug: Setmelanotide
    Sponsor:   Rhythm Pharmaceuticals, Inc.
    Recruiting

  • Conditions:   Leukemia;   Down Syndrome
    Intervention:  
    Sponsor:   St. Jude Children's Research Hospital
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Interventions:   Drug: Cannabidiol;   Drug: Placebo
    Sponsor:   INSYS Therapeutics Inc
    Recruiting

  • Conditions:   Williams Syndrome;   Supravalvular Aortic Stenosis;   Cardiovascular Disease
    Intervention:  
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Intervention:   Other: Data collection
    Sponsor:   University Hospital, Toulouse
    Recruiting

  • Condition:   Prader-Willi Syndrome
    Interventions:   Drug: Oxytocin (OXT) continuous;   Drug: Placebo;   Drug: Placebo continuous;   Drug: Oxytocin
    Sponsor:   University Hospital, Toulouse
    Recruiting

  • Conditions:   Activating RAS Mutation;   Blasts Under 20 Percent of Bone Marrow Nucleated Cells;   Blasts Under 20 Percent of Peripheral Blood White Cells;   Juvenile Myelomonocytic Leukemia;   Monosomy 7;   Neurofibromatosis Type 1;   NF1 Gene Mutation;   PTPN11 Gene Mutation;   Splenomegaly
    Interventions:   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Trametinib
    Sponsor:   National Cancer Institute (NCI)
    Recruiting

  • Condition:   Down Syndrome
    Interventions:   Biological: ACI-24 low dose;   Biological: ACI-24 high dose;   Biological: Placebo
    Sponsors:   AC Immune SA;   National Institute on Aging (NIA);   Alzheimer's Disease Cooperative Study (ADCS);   LuMind Research Down Syndrome Foundation
    Recruiting

  • Conditions:   Williams Syndrome;   Supravalvular Aortic Stenosis;   Cardiovascular Disease
    Intervention:  
    Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting

  • Condition:   Down Syndrome
    Intervention:   Device: photographs
    Sponsors:   Kevin Cleary;   Children's Research Institute;   George Washington University;   Chiang Mai University
    Recruiting

  • Conditions:   Alzheimer Disease;   Down Syndrome;   Mild Cognitive Impairment
    Intervention:  
    Sponsor:   University of Colorado, Denver
    Recruiting

  • Conditions:   Developmental Disabilities;   Weight Loss;   Body Weight;   Down Syndrome;   Body Weight Changes;   Intellectual Disability
    Interventions:   Dietary Supplement: Enhanced Stop Light Diet (eSLD);   Dietary Supplement: Conventional Diet (CD);   Behavioral: Face-to-face (FTF);   Behavioral: Technology (TECH);   Other: iPad with FaceTime
    Sponsors:   University of Kansas Medical Center;   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Metabolism and Nutrition Disorder;   Obesity
    Interventions:   Drug: liraglutide;   Drug: placebo
    Sponsor:   Novo Nordisk A/S
    Recruiting

  • Condition:   Down Syndrome
    Intervention:   Device: High definition transcranial direct current stimulation
    Sponsor:   University of Wisconsin, Madison
    Recruiting

  • Conditions:   Down Syndrome;   Polyendocrinopathies, Autoimmune;   Respiratory Tract Infections;   Autoimmunity
    Intervention:   Other: Phlebotomy
    Sponsor:   University of Colorado, Denver
    Recruiting

  • Conditions:   Sleep Apnea, Obstructive;   Down Syndrome
    Intervention:   Device: Inspire® Upper Airway Simulation System (Model 3028 IPG )
    Sponsors:   Christopher Hartnick, M.D.;   Massachusetts General Hospital;   University Hospitals Cleveland Medical Center;   Emory University;   Children's Hospital Medical Center, Cincinnati;   Inspire Medical Systems, Inc.;   University of Pittsburgh;   Children's Hospital of The King's Daughters;   Stanford University;   University of Texas Southwestern Medical Center;   Texas Children's Hospital;   Oregon Health and Science University;   C.S. Mott Children's Hospital;   Seattle Children's Hospital;   Children's Hospital of Philadelphia
    Recruiting

  • Conditions:   Down Syndrome;   Intellectual Disability
    Interventions:   Drug: Memantine;   Drug: Placebo
    Sponsors:   University Hospitals Cleveland Medical Center;   Alana USA Foundation
    Recruiting

  • Condition:   Down Syndrome
    Intervention:   Device: monitoring BIS in both groups
    Sponsor:   Milton S. Hershey Medical Center
    Recruiting

  • Condition:   Fuchs Endothelial Corneal Dystrophy
    Interventions:   Other: Collection of datas;   Biological: blood sample;   Other: slit lamp examination
    Sponsors:   Centre Hospitalier Universitaire de Saint Etienne;   Kyoto University, Graduate School of Medicine
    Recruiting

  • Condition:   Down Syndrome
    Intervention:  
    Sponsor:   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
    Recruiting

  • Conditions:   Congenital Hyperinsulinism;   Beckwith-Wiedemann Syndrome;   Insulinoma
    Intervention:   Drug: 18F-DOPA
    Sponsor:   Children's Hospital of Philadelphia
    Available

  • Conditions:   Immune Deficiency Disorders;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorders;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
    Intervention:   Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
    Sponsor:   Washington University School of Medicine
    Recruiting

  • Conditions:   Down Syndrome;   Mild Cognitive Impairment
    Interventions:   Drug: Low Dose Nicotine (7mg);   Drug: Moderate Dose Nicotine (14mg)
    Sponsor:   Vanderbilt University Medical Center
    Recruiting

  • Conditions:   Complete DiGeorge Anomaly;   DiGeorge Syndrome;   DiGeorge Anomaly;   Complete DiGeorge Syndrome
    Interventions:   Biological: Thymus Tissue for Transplantation;   Procedure: Blood Draw;   Drug: Rabbit anti-thymocyte globulin;   Drug: Cyclosporine;   Drug: Tacrolimus;   Drug: Methylprednisolone or Prednisolone;   Drug: Basiliximab;   Drug: Mycophenolate mofetil
    Sponsors:   M. Louise Markert;   National Institutes of Health (NIH);   National Institute of Allergy and Infectious Diseases (NIAID);   Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD);   Enzyvant Therapeutics GmbH
    Available

  • Condition:   Williams Syndrome
    Intervention:  
    Sponsor:   National Institute of Mental Health (NIMH)
    Recruiting

  • Condition:   Holoprosencephaly
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting

  • Conditions:   Holoprosencephaly;   HPE;   Developmental Delay Disorders;   Brain Disorders
    Intervention:  
    Sponsor:   National Human Genome Research Institute (NHGRI)
    Recruiting

  • Condition:   Ultrasound Fetal Medicine
    Intervention:   Other: Survey
    Sponsor:   University Hospital, Limoges
    Not yet recruiting

  • Conditions:   Leukemia;   Mucositis;   Oral Complications
    Interventions:   Biological: palifermin;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: imatinib mesylate;   Drug: melphalan;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: vincristine sulfate;   Procedure: allogeneic hematopoietic stem cell transplantation;   Radiation: total-body irradiation
    Sponsor:   University College, London
    Recruiting

  • Conditions:   15q Duplication Syndrome;   CDKL5 Deficiency Disease
    Intervention:   Drug: TAK-935
    Sponsors:   Takeda;   Ovid Therapeutics Inc.
    Recruiting

  • Conditions:   Frontotemporal Dementia;   Frontotemporal Degeneration;   Frontotemporal Dementia, Behavioral Variant;   FTD
    Intervention:   Other: Telephone Interview
    Sponsors:   Johns Hopkins Bloomberg School of Public Health;   National Institutes of Health (NIH)
    Recruiting